Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6773)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2016 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol 2016; 22(46): 10210-10218 [PMID: 28028369 DOI: 10.3748/wjg.v22.i46.10210] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i46/10210.htm |
| Number | Citing Articles |
| 1 |
Qian Zhang, Xiaoqing Liu, Xicheng Pang, Huimin Wang, Jinjie Du, Hong Ren, Peng Hu. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels. Cytokine 2023; 164: 156140 doi: 10.1016/j.cyto.2023.156140
|
| 2 |
Feng-Ping Wu, Ying Yang, Mei Li, Yi-Xin Liu, Ya-Ping Li, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Shuang-Suo Dang. Add-on pegylated interferon augments hepatitis B surface antigen clearance <i>vs</i> continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World Journal of Gastroenterology 2020; 26(13): 1525-1539 doi: 10.3748/wjg.v26.i13.1525
|
| 3 |
Ming-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(10): 779 doi: 10.1080/17425255.2019.1678584
|
| 4 |
Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Ritsuzo Kozuka, Hideki Fujii, Sawako Uchida‐Kobayashi, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhide Higuchi, Masaki Saito, Hirayuki Enomoto, Norifumi Kawada. Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B. Hepatology Research 2018; 48(6): 459 doi: 10.1111/hepr.13050
|
| 5 |
Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana. Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management. World Journal of Hepatology 2024; 16(4): 550-565 doi: 10.4254/wjh.v16.i4.550
|
| 6 |
Mariana Alves Fonseca, Joanna Zhi Jie Ling, Omar Al‐Siyabi, Vanessa Co‐Tanko, Edwin Chan, Seng Gee Lim. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta‐analysis. Journal of Viral Hepatitis 2020; 27(7): 650 doi: 10.1111/jvh.13283
|
| 7 |
Peter Wigfield, Urbano Sbarigia, Mahmoud Hashim, Talitha Vincken, Bart Heeg. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. PharmacoEconomics - Open 2020; 4(3): 403 doi: 10.1007/s41669-019-00175-w
|
| 8 |
Jing Huang, Ka Zhang, Wenli Chen, Jinyao Liao, Xiaodan Luo, Ren Chen. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-13747-9
|
| 9 |
K. Qiu, B. Liu, S.‐Y. Li, H. Li, Z.‐W. Chen, A.‐R. Luo, M.‐L. Peng, H. Ren, P. Hu. Systematic review with meta‐analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Alimentary Pharmacology & Therapeutics 2018; 47(10): 1340 doi: 10.1111/apt.14629
|
| 10 |
Jun‐Hao Chu, Yan Huang, Dong‐Ying Xie, Hong Deng, Jia Wei, Yu‐Juan Guan, Guo‐Jun Li, Yi‐Lan Zeng, Jia‐Hong Yang, Xin‐Yue Chen, Jia Shang, Jia‐Bin Li, Na Gao, Zhi‐Liang Gao. Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients. Journal of Viral Hepatitis 2022; 29(9): 765 doi: 10.1111/jvh.13722
|
| 11 |
Hong Ren, Yan Huang. Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. Journal of Viral Hepatitis 2019; 26(S1): 5 doi: 10.1111/jvh.13150
|
| 12 |
Leen Slaets, Filip De Ridder, Oliver Lenz, Maria Beumont, Paul Meyvisch, Thierry Verbinnen. Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. GastroHep 2020; 2(3): 106 doi: 10.1002/ygh2.393
|